Recruiting PHASE2 INTERVENTIONAL 1-arm NCT04891016

Toripalimab Plus FLOT in Locally Advanced Gastric Cancer

Toripalimab Combined With FLOT Regimen in Locally Advanced Gastric cancer-a Prospective, Open, Multi-center, Phase Ⅱ Clinical Study

Sponsor: Henan Cancer Hospital

Conditions Chemotherapy Immune Checkpoint Inhibitor Locally Advanced Gastric Carcinoma

Interventions FLOT combined with toripalimab

Updated 4 times since 2021 Last updated: Jun 5, 2024 Started: Jun 25, 2021 Primary completion: Dec 31, 2025 Completion: Dec 31, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04891016, this PHASE2 trial focuses on Chemotherapy and Immune Checkpoint Inhibitor and remains actively recruiting participants. Sponsored by Henan Cancer Hospital, it has been updated 4 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Mar 2022 — Jul 2024 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jun 2021 — Mar 2022 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Henan Cancer Hospital

Data source: Henan Cancer Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zhengzhou, China